SEARCH:   Advanced

Blood, 15 November 2006, Vol. 108, No. 10, pp. 3406-3413. Prepublished online as a Blood First Edition Paper on July 27, 2006; DOI 10.1182/blood-2006-04-018705. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-04-018705v1 108/10/3406    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Mumprecht, S. Articles by Ochsenbein, A. F. Search for Related Content PubMed PubMed Citation Articles by Mumprecht, S. Articles by Ochsenbein, A. F. Related Collections Immunobiology Neoplasia Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections Sabine Mumprecht, Matthias Matter, Viktor Pavelic, and Adrian F. Ochsenbein From Tumor Immunology, Department of Clinical Research, University of Berne, Berne, Switzerland; and Institute for Medical Oncology, Inselspital, Berne, Switzerland. Imatinib mesylate (imatinib) is a potent inhibitor of defined tyrosine kinases (TKs) and is effective in the treatment of malignancies characterized by constitutive activation of these TKs such as chronic myeloid leukemia and gastrointestinal stromal tumors. TKs also play an important role in T-cell receptor (TCR) signal transduction. Inhibitory as well as stimulating effects of imatinib on T cells and dendritic cells have been described. Here, we analyzed the effects of imatinib treatment on antiviral immune responses in vivo. Primary cytotoxic T-cell (CTL) responses were not impaired in imatinib-treated mice after infection with lymphocytic choriomeningitis virus (LCMV) or after immunization with a tumor cell line expressing LCMV glycoprotein (LCMV-GP). Similarly, neutralizing antibody responses to vesicular stomatitis virus (VSV) were not affected. In contrast, secondary expansion of LCMV-specific memory CTLs was reduced in vitro and in vivo, resulting in impaired protection against reinfection. In addition, imatinib treatment delayed the onset of diabetes in a CTL-induced diabetes model. In summary, imatinib treatment in vivo selectively inhibits the expansion of antigen-experienced memory CTLs without affecting primary T- or B-cell responses. Therefore, imatinib may be efficacious in the suppression of CTL-mediated immunopathology in autoimmune diseases without the risk of acquiring viral infections. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Mumprecht, C. Schurch, J. Schwaller, M. Solenthaler, and A. F. Ochsenbein Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression Blood, August 20, 2009; 114(8): 1528 - 1536. [Abstract] [Full Text] [PDF] S. Mumprecht, C. Claus, C. Schurch, V. Pavelic, M. S. Matter, and A. F. Ochsenbein Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells Blood, May 7, 2009; 113(19): 4681 - 4689. [Abstract] [Full Text] [PDF] J. M. A. Daniels, A. Vonk-Noordegraaf, J. J. W. M. Janssen, P. E. Postmus, and R. van Altena Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia Eur. Respir. J., March 1, 2009; 33(3): 670 - 672. [Abstract] [Full Text] [PDF] D. H. Kim, S. Kamel-Reid, H. Chang, R. Sutherland, C. W. Jung, H.-J. Kim, J.-J. Lee, and J. H. Lipton Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia Haematologica, January 1, 2009; 94(1): 135 - 139. [Abstract] [Full Text] [PDF] C. Louvet, G. L. Szot, J. Lang, M. R. Lee, N. Martinier, G. Bollag, S. Zhu, A. Weiss, and J. A. Bluestone Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice PNAS, December 2, 2008; 105(48): 18895 - 18900. [Abstract] [Full Text] [PDF] N. Larmonier, N. Janikashvili, C. J. LaCasse, C. B. Larmonier, J. Cantrell, E. Situ, T. Lundeen, B. Bonnotte, and E. Katsanis Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors J. Immunol., November 15, 2008; 181(10): 6955 - 6963. [Abstract] [Full Text] [PDF] R. Santachiara, R. Maffei, S. Martinelli, A. Arcari, F. Piacentini, E. Trabacchi, P. Alfieri, A. Ferrari, G. Leonardi, G. Luppi, et al. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor Haematologica, August 1, 2008; 93(8): 1252 - 1255. [Abstract] [Full Text] [PDF] R. Weichsel, C. Dix, L. Wooldridge, M. Clement, A. Fenton-May, A. K. Sewell, J. Zezula, E. Greiner, E. Gostick, D. A. Price, et al. Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib Clin. Cancer Res., April 15, 2008; 14(8): 2484 - 2491. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020